DK3192524T3 - Hgf præparat egnet til behandling af neurologiske lidelser - Google Patents
Hgf præparat egnet til behandling af neurologiske lidelser Download PDFInfo
- Publication number
- DK3192524T3 DK3192524T3 DK15840062.2T DK15840062T DK3192524T3 DK 3192524 T3 DK3192524 T3 DK 3192524T3 DK 15840062 T DK15840062 T DK 15840062T DK 3192524 T3 DK3192524 T3 DK 3192524T3
- Authority
- DK
- Denmark
- Prior art keywords
- treatment
- neurological disorders
- preparation suitable
- hgf preparation
- hgf
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014184475 | 2014-09-10 | ||
| PCT/JP2015/074310 WO2016039163A1 (ja) | 2014-09-10 | 2015-08-27 | 神経疾患の治療に適したｈｇｆ製剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3192524T3 true DK3192524T3 (da) | 2022-02-14 |
Family
ID=55458917
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15840062.2T DK3192524T3 (da) | 2014-09-10 | 2015-08-27 | Hgf præparat egnet til behandling af neurologiske lidelser |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10213485B2 (da) |
| EP (1) | EP3192524B1 (da) |
| JP (2) | JP6281992B2 (da) |
| KR (1) | KR101950916B1 (da) |
| CN (1) | CN106714823A (da) |
| CA (1) | CA2958342C (da) |
| DK (1) | DK3192524T3 (da) |
| ES (1) | ES2907125T3 (da) |
| PT (1) | PT3192524T (da) |
| WO (1) | WO2016039163A1 (da) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106714823A (zh) * | 2014-09-10 | 2017-05-24 | 克霖固鲁制药股份有限公司 | 适合神经系统疾病的治疗的hgf制剂 |
| CA3040687A1 (en) * | 2016-10-14 | 2018-04-19 | Childrens' Medical Center Corporation | Compositions and methods for treating diseases and disorders of the central nervous system |
| CA3050691A1 (en) | 2017-01-17 | 2018-07-26 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating lysosomal storage diseases and disorders |
| KR102245539B1 (ko) * | 2018-02-12 | 2021-04-29 | 주식회사 지앤피바이오사이언스 | 코어-쉘 구조의 마이크로 입자를 유효성분으로 포함하는 성장인자 유전자 발현 증가용 조성물 |
| CA3106085A1 (en) * | 2018-07-17 | 2020-04-23 | Helixmith Co., Ltd. | Treatment of neuropathy with igf-1-encoding dna constructs and hgf-encoding dna constructs |
| CN109535243B (zh) * | 2019-01-07 | 2019-09-24 | 北京诺思兰德生物技术股份有限公司 | 人肝细胞生长因子突变体及其应用 |
| AU2022272740A1 (en) * | 2021-05-14 | 2023-11-02 | Claris Biotherapeutics, Inc. | Compositions of growth factor for the treatment of eye disease |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ232813A (en) | 1989-03-10 | 1992-08-26 | Snow Brand Milk Products Co Ltd | Human fibroblast glycoprotein, cell differentiation, blood vessel endothelial cell growth factor, cellular immunology inforcing factor of 78 or 74 thousand daltons plus or minus two thousand daltons |
| JP3680114B2 (ja) * | 1993-09-17 | 2005-08-10 | 敏一 中村 | 脳神経障害治療剤 |
| JP3927248B2 (ja) | 1995-07-11 | 2007-06-06 | 第一製薬株式会社 | Ｈｇｆ凍結乾燥製剤 |
| US6685940B2 (en) * | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| CN100448482C (zh) * | 1999-05-31 | 2009-01-07 | 三菱化学株式会社 | Hgf冻干制剂 |
| JP5442173B2 (ja) * | 2000-09-14 | 2014-03-12 | 敏一 中村 | 筋萎縮性側索硬化症治療剤 |
| US20030176347A1 (en) * | 2003-05-14 | 2003-09-18 | Toshikazu Nakamura | Remedies for amyotrophic lateral sclerosis |
| NZ530545A (en) * | 2001-07-11 | 2006-10-27 | Maxygen Holdings Ltd | Specific conjugates comprising a polypeptide exhibiting G-CSF activity and a non-polypeptide moiety |
| GB0202633D0 (en) * | 2002-02-05 | 2002-03-20 | Delta Biotechnology Ltd | Stabilization of protein preparations |
| GB2414395B (en) * | 2003-03-26 | 2007-10-31 | Kringle Pharma Inc | Asthma preparation |
| CA2541603A1 (en) | 2003-10-14 | 2005-04-21 | Kringle Pharma Inc. | Agent for improving mental disorders |
| US7265092B2 (en) * | 2004-09-30 | 2007-09-04 | Kai Pharmaceuticals, Inc. | Pharmaceutical formulation |
| DE602006021708D1 (de) * | 2005-03-07 | 2011-06-16 | Mondobiotech Ag | Formulierung für aviptadil |
| CA2649820C (en) | 2006-04-20 | 2017-12-05 | Kringle Pharma Inc. | Agent for treating polyglutamine aggregation-caused disease or suppressing onset thereof |
| US7935791B2 (en) * | 2006-12-18 | 2011-05-03 | Genentech, Inc. | Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-related diseases |
| WO2008102452A1 (ja) | 2007-02-22 | 2008-08-28 | Kringle Pharma Inc. | Ｈｇｆ製剤 |
| WO2008105088A1 (ja) | 2007-02-28 | 2008-09-04 | Keio University | 脊髄損傷治療薬剤 |
| WO2010008023A1 (ja) * | 2008-07-18 | 2010-01-21 | クリングルファーマ株式会社 | 骨延長促進剤 |
| WO2010041716A1 (ja) * | 2008-10-10 | 2010-04-15 | クリングルファーマ株式会社 | 腱骨移行部組織または靭帯骨移行部組織の再生促進剤 |
| CN101785856B (zh) * | 2009-01-22 | 2012-06-06 | 齐鲁制药有限公司 | 稳定等渗的去氨普酶α1或其突变体制剂 |
| JP2011173916A (ja) * | 2011-05-02 | 2011-09-08 | Toshiichi Nakamura | 筋萎縮性側索硬化症治療剤 |
| EP2928486A1 (en) * | 2012-12-07 | 2015-10-14 | Shire Human Genetic Therapies, Inc. | Methods and compositions for intrathecally administered treatment of mucupolysaccharidosis type iiia |
| EP2970396B1 (en) * | 2013-03-15 | 2022-02-23 | Biological Mimetics, Inc. | Immunogenic human rhinovirus (hrv) compositions |
| CN106714823A (zh) * | 2014-09-10 | 2017-05-24 | 克霖固鲁制药股份有限公司 | 适合神经系统疾病的治疗的hgf制剂 |
-
2015
- 2015-08-27 CN CN201580048600.8A patent/CN106714823A/zh active Pending
- 2015-08-27 WO PCT/JP2015/074310 patent/WO2016039163A1/ja active Application Filing
- 2015-08-27 EP EP15840062.2A patent/EP3192524B1/en active Active
- 2015-08-27 KR KR1020177009589A patent/KR101950916B1/ko active IP Right Grant
- 2015-08-27 US US15/507,886 patent/US10213485B2/en active Active
- 2015-08-27 PT PT158400622T patent/PT3192524T/pt unknown
- 2015-08-27 DK DK15840062.2T patent/DK3192524T3/da active
- 2015-08-27 JP JP2016547358A patent/JP6281992B2/ja active Active
- 2015-08-27 ES ES15840062T patent/ES2907125T3/es active Active
- 2015-08-27 CA CA2958342A patent/CA2958342C/en active Active
-
2017
- 2017-12-08 JP JP2017236414A patent/JP2018044000A/ja active Pending
-
2018
- 2018-12-28 US US16/235,132 patent/US10702582B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2958342A1 (en) | 2016-03-17 |
| US10213485B2 (en) | 2019-02-26 |
| EP3192524A4 (en) | 2018-07-04 |
| ES2907125T3 (es) | 2022-04-22 |
| WO2016039163A1 (ja) | 2016-03-17 |
| CA2958342C (en) | 2019-09-24 |
| PT3192524T (pt) | 2022-02-17 |
| EP3192524B1 (en) | 2021-12-29 |
| JPWO2016039163A1 (ja) | 2017-06-22 |
| KR20170054465A (ko) | 2017-05-17 |
| US20170333527A1 (en) | 2017-11-23 |
| US10702582B2 (en) | 2020-07-07 |
| KR101950916B1 (ko) | 2019-02-21 |
| EP3192524A1 (en) | 2017-07-19 |
| CN106714823A (zh) | 2017-05-24 |
| JP2018044000A (ja) | 2018-03-22 |
| US20190117732A1 (en) | 2019-04-25 |
| JP6281992B2 (ja) | 2018-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3570844T3 (da) | Azolopyrimidin til behandlingen af kræftrelaterede lidelser | |
| DK3185876T3 (da) | Sammensætninger og fremgangsmåder til behandling af neurologiske lidelser | |
| DK3212233T3 (da) | Kombinationsterapi til behandling af sygdom | |
| DK3261640T3 (da) | 5ht-agonister til behandling af epilepsilidelser | |
| DK3139925T3 (da) | Valbenazin-doseringssystem til behandling af hyperkinetiske bevægelsesforstyrrelser | |
| DK3125875T3 (da) | Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande | |
| DK3119397T3 (da) | Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser | |
| DK3096741T3 (da) | Fremgangsmåde til fremstillingen af hybridosomer | |
| DK3307262T3 (da) | Forbindelser til anvendelse ved behandling af neuromuskulære lidelser | |
| DK3240612T3 (da) | Fremgangsmåder til behandling af nethindesygdomme | |
| DK3174858T3 (da) | Fremgangsmåde til fremstilling af pyrazoler | |
| DK3102213T3 (da) | Farmaceutiske sammensætninger til behandlingen af inflammatoriske lidelser | |
| DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
| DK3148529T3 (da) | Forbindelser til behandling af hjernecancer | |
| DK3390390T3 (da) | Bipyrazolylderivater egnede til behandling af autoimmunsygdomme | |
| DK3169328T3 (da) | Quinolinderivater til behandling af inflammationssygdomme | |
| DK3192524T3 (da) | Hgf præparat egnet til behandling af neurologiske lidelser | |
| DK3233813T3 (da) | Fremgangsmåder til fremstilling af oxathiazin-lignende forbindelser | |
| DK3439661T3 (da) | Fremgangsmåder til behandling af øjenlidelser | |
| DK3548061T3 (da) | Behandling af neurologiske sygdomme | |
| DK3210973T3 (da) | Heteroarylforbindelser til behandling af oftalmiske sygdomme | |
| SG11201708181RA (en) | Methods for the treatment of inflammatory disorders | |
| DK3209295T3 (da) | Fremgangsmåder til behandling af øjenlidelser | |
| DK3200828T3 (da) | Intranasale sammensætninger til behandling af neurologiske og neurodegenerative sygdomme og forstyrrelser | |
| DK3096775T3 (da) | SOCS-mimetika til behandling af sygdomme |